20 Takeover Rumors Hedge Funds Are Buying

Page 11 of 18

8. Nuvalent, Inc. (NASDAQ:NUVL)

No. of Hedge Funds: 50

Based in Massachusetts, a clinical-stage biopharmaceutical company, Nuvalent, Inc. (NASDAQ:NUVL) is focused on developing targeted therapies for cancers driven by oncogenic kinase alterations. Its pipeline includes novel ROS1-, ALK-, and HER2-driven tumor inhibitors, emphasizing CNS penetration. The company acquires a competitive advantage with structure-based drug design and strategic partnerships. The unmet needs in precision oncology support the company’s address of resistance mutations in existing therapies.

Nuvalent, Inc. (NASDAQ:NUVL) sees its takeover rumors rise in 2025, following the appointment of its new board member, Grant Bogle. Grant has 40 years of experience in the biotech industry and has taken the position of CEO of Epizyme, which was acquired in 2022. Nuvalent, Inc. (NASDAQ:NUVL) also attracts potential acquirers with its $1.2 billion cash runway into 2028. Additionally, the company is scheduled to introduce its first targeted cancer treatment in 2026. Though no names have been provided by the experts, analysts, and the company itself regarding the potential buyer, the appointment of M&A expertise, the company’s robust pipeline, and its strong financial position increase the possibility of a takeover.

Adding value to this rumored takeover, 50 hedge funds are backing the company’s stock, as per Insider Monkey’s Q4 2024 database. The hedge funds reflect strong institutional confidence in the company’s future progress, including its potential takeover.

Page 11 of 18